BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buffolo F, Tetti M, Mulatero P, Monticone S. Aldosterone as a Mediator of Cardiovascular Damage. Hypertension 2022;79:1899-911. [PMID: 35766038 DOI: 10.1161/HYPERTENSIONAHA.122.17964] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Solanki P, Gwini SM, Libianto R, Gabb G, Shen J, Young MJ, Fuller PJ, Yang J. Risky business: a single-centre cross-sectional analysis of calculated cardiovascular risk in patients with primary aldosteronism and essential hypertension. BMJ Open 2022;12:e062406. [PMID: 36375972 DOI: 10.1136/bmjopen-2022-062406] [Reference Citation Analysis]
2 Carsote M. The Entity of Connshing Syndrome: Primary Aldosteronism with Autonomous Cortisol Secretion. Diagnostics 2022;12:2772. [DOI: 10.3390/diagnostics12112772] [Reference Citation Analysis]
3 Januszewicz A, Mulatero P, Dobrowolski P, Monticone S, Van der Niepen P, Sarafidis P, Reincke M, Rexhaj E, Eisenhofer G, Januszewicz M, Kasiakogias A, Kreutz R, Lenders JW, Muiesan ML, Persu A, Agabiti-rosei E, Soria R, Śpiewak M, Prejbisz A, Messerli FH. Cardiac Phenotypes in Secondary Hypertension. Journal of the American College of Cardiology 2022;80:1480-1497. [DOI: 10.1016/j.jacc.2022.08.714] [Reference Citation Analysis]
4 Mulatero P, Bertello C, Veglio F, Monticone S. Approach to the Patient on Antihypertensive Therapy: Screen for Primary Aldosteronism. J Clin Endocrinol Metab 2022:dgac460. [PMID: 35964152 DOI: 10.1210/clinem/dgac460] [Reference Citation Analysis]